Industries > Pharma > Top 25 Dermatological Drugs Manufacturers 2019

Top 25 Dermatological Drugs Manufacturers 2019

Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies

PUBLISHED: 15 April 2019
PAGES: 176
PRODUCT CODE: PHA0380

Clear
WOOCS 2.2.1

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 108 tables and 71 figures– all unavailable elsewhere.

The 176-page report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

• Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
• Abbvie Inc.
• Allergan plc
• Almirall S.A.
• Amgen
• Astellas
• Bayer
• Concert Pharmaceuticals
• Eli Lilly and Company
• Galderma
• GlaxoSmithkline plc (GSK)
• Johnson & Johnson (J&J)
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma
• Other companies

• For each company, the report provides information and discussion on:
• Total revenue forecast to 2028
• Dermatology segment revenue forecast to 2028
• The leading dermatology drugs revenue forecast to 2028
• Drugs portfolio
• Recent developments

• The report provides revenue forecast to 2028 for the following dermatological drugs:
• Epiduo
• Differin
• Stelara
• Remicade
• Humira
• Valtrex
• Lamisil
• Bactroban
• Dermovate
• Zyvox
• Protopic
• Solodyn
• Ziana
• Taltz
• Cosentyx
• Aczone
• Cubicin
• Elocon
• Absorica /Epirus
• Enbrel
• Doryx
• Canesten
• Bepanthen/Bepanthol

• Key questions answered by this report:
• How is the Dermatological Drugs Manufacturers market evolving?
• What is driving and restraining the Dermatological Drugs Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Dermatological Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories